🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

UBS revises Coloplast rating to 'neutral,' sees lower risk

Published 12/11/2024, 08:57 AM
© Reuters.
COLOb
-
CLPBY
-

Investing.com -- UBS has revised its rating on Coloplast (CSE:COLOb) A/S, upgrading the Danish healthcare company to "neutral" from "sell." 

This revision reflects changes in market dynamics and a reassessment of risk and reward linked to the company’s operations and valuation. 

Analysts at UBS cited several factors supporting the upgrade, including recalibrated expectations around competitive pressures and investments in growth areas such as wound biologics and continence care.

Previously, UBS expressed concerns about Coloplast’s ability to maintain its premium valuation amid competitive challenges in its key markets, particularly in Ostomy and Urology. 

The brokerage noted that market expectations were overly optimistic regarding potential reimbursement benefits, especially in the U.S. continence market. These factors contributed to UBS's prior "sell" rating.

However, as per the updated analysis, many of the risks highlighted earlier have either diminished or been better accounted for in the stock's current valuation. 

The market has adjusted to more conservative expectations, with the company now trading at a 40% sector premium, aligning with historical averages. 

Moreover, the publication of final reimbursement rulings for Kerecis in the U.S. has removed a major overhang, adding to the reduced uncertainty.

UBS also flagged recent structural changes, including Coloplast’s disposal of its skin care portfolio, which has led to minor revenue adjustments but no material impact on earnings estimates.

Going forward, the brokerage expects Coloplast to deliver steady growth, projecting an 8% compound annual revenue growth rate from 2024 to 2028 and an 11% increase in earnings per share over the same period. 

At its price target of DKK 858, the stock would trade at 33 times the estimated 2025 earnings, justifying the neutral stance.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.